What's new — Type 1 diabetes¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 2 |
| last 2 months | 15 |
| last 3 months | 17 |
| last 6 months | 24 |
| last year | 39 |
| older than a year | 237 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-02 | Population-Based Screening for Type 1 Diabetes in Czechia: Results From the First 1% of the Paediatric Population — Diabetes Obes Metab ([PMID 42935169](https://pubmed.ncbi.nlm.nih.gov/42935169/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-10-02 | Maternal Autoimmune Diseases During Pregnancy and Offspring Type 1 Diabetes — JAMA Pediatr ([PMID 42931746](https://pubmed.ncbi.nlm.nih.gov/42931746/){target="_blank" rel="noopener"}) | genetics-and-environmental-triggers |
| 2026-10-01 | Maternal antibody transfer confounds type 1 diabetes screening in infancy: results from the French TRAKR cohort — Diabetes Metab ([PMID 42880695](https://pubmed.ncbi.nlm.nih.gov/42880695/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-10-01 | Predictive autoantibodies before the diagnosis of type I diabetes in adults — PLoS One ([PMID 42879429](https://pubmed.ncbi.nlm.nih.gov/42879429/){target="_blank" rel="noopener"}) | staging-and-natural-history |
| 2026-10-01 | Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes — Diabetes Care ([PMID 42520060](https://pubmed.ncbi.nlm.nih.gov/42520060/){target="_blank" rel="noopener"}) | disease-modifying-immunotherapy |
| 2026-09-03 | Correction: The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) — Diabetologia ([PMID 42814152](https://pubmed.ncbi.nlm.nih.gov/42814152/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-03 | Gene-edited hypoimmune islets as a cure for type 1 diabetes: a review of the immunological challenges — Expert Opin Biol Ther ([PMID 42626948](https://pubmed.ncbi.nlm.nih.gov/42626948/){target="_blank" rel="noopener"}) | beta-cell-replacement |
| 2026-09-02 | Delayed time to stage 3 type 1 diabetes after GAD-alum treatment in HLA-DR3-DQ2-positive children: follow-up of the randomised placebo-controlled Diabetes Prevention - Immune Tolerance trial — Diabetologia ([PMID 42806034](https://pubmed.ncbi.nlm.nih.gov/42806034/){target="_blank" rel="noopener"}) | disease-modifying-immunotherapy |
| 2026-09-02 | An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults — Diabetologia ([PMID 42771181](https://pubmed.ncbi.nlm.nih.gov/42771181/){target="_blank" rel="noopener"}) | guidelines, insulin-therapy-and-technology |
| 2026-09-01 | Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE — Kidney Int Rep ([PMID 42927222](https://pubmed.ncbi.nlm.nih.gov/42927222/){target="_blank" rel="noopener"}) | complications |
| 2026-09-01 | The transition of youth with diabetes from paediatric to adult diabetes care services: a consensus report of the joint working group of the International Society for Pediatric and Adolescent Diabetes (ISPAD), the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) — Horm Res Paediatr ([PMID 42784528](https://pubmed.ncbi.nlm.nih.gov/42784528/){target="_blank" rel="noopener"}) | guidelines, psychosocial-and-behavioral |
| 2026-09-01 | The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) — Diabetologia ([PMID 42747450](https://pubmed.ncbi.nlm.nih.gov/42747450/){target="_blank" rel="noopener"}) | guidelines, insulin-therapy-and-technology |
| 2026-09-01 | 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetes — Diabetologia ([PMID 42744915](https://pubmed.ncbi.nlm.nih.gov/42744915/){target="_blank" rel="noopener"}) | guidelines, psychosocial-and-behavioral |
| 2026-09-01 | International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process — Diabetologia ([PMID 42720753](https://pubmed.ncbi.nlm.nih.gov/42720753/){target="_blank" rel="noopener"}) | guidelines, screening-and-early-detection |
| 2026-09-01 | Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial — Diabetologia ([PMID 42720752](https://pubmed.ncbi.nlm.nih.gov/42720752/){target="_blank" rel="noopener"}) | disease-modifying-immunotherapy |
| 2026-08-03 | Simultaneous Pancreas-Kidney Transplantation Versus Kidney Transplantation Alone in Type 1 Diabetes: Does Pancreas Transplantation Improve Clinical Outcomes? A Systematic Review and Exploratory Meta-Analysis — Med Sci (Basel) ([PMID 42646588](https://pubmed.ncbi.nlm.nih.gov/42646588/){target="_blank" rel="noopener"}) | beta-cell-replacement |
| 2026-08-02 | Natural History of Mild Non-Proliferative Diabetic Retinopathy in Adults with Type 1 Diabetes Under Contemporary Diabetes Care — Diabetes Technol Ther ([PMID 42626886](https://pubmed.ncbi.nlm.nih.gov/42626886/){target="_blank" rel="noopener"}) | complications |
| 2026-08-01 | Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial — Diabetes Care ([PMID 42258447](https://pubmed.ncbi.nlm.nih.gov/42258447/){target="_blank" rel="noopener"}) | complications |
| 2026-07-02 | Epidemiological and clinical insights from Type 1 Diabetes Global Registries: A systematic review and meta-analysis — Diabetes Metab Syndr ([PMID 42551241](https://pubmed.ncbi.nlm.nih.gov/42551241/){target="_blank" rel="noopener"}) | complications, epidemiology-and-burden, overview |
| 2026-07-02 | Global prevalence and correlates of diabetes distress in type 1 diabetes: A systematic review and meta-analysis — Diabetes Res Clin Pract ([PMID 42486409](https://pubmed.ncbi.nlm.nih.gov/42486409/){target="_blank" rel="noopener"}) | overview, patient-experience-and-advocacy, psychosocial-and-behavioral |
| 2026-07-01 | Contemporary Diabetes Technology and the Patient Experience — JAMA Netw Open ([PMID 42479430](https://pubmed.ncbi.nlm.nih.gov/42479430/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-07-01 | Reduced Prevalence of Impaired Awareness of Hypoglycemia Over Two Decades in Population-Based Samples of Youth With Type 1 Diabetes — Diabetes Care ([PMID 42138725](https://pubmed.ncbi.nlm.nih.gov/42138725/){target="_blank" rel="noopener"}) | hypoglycemia |
| 2026-07-01 | Accounting for Age-Related Increases in HbA1c More Accurately Quantifies Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Adults — Diabetes Care ([PMID 42090204](https://pubmed.ncbi.nlm.nih.gov/42090204/){target="_blank" rel="noopener"}) | screening-and-early-detection, staging-and-natural-history |
| 2026-06-01 | Worldwide prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes: A systematic review and meta-analysis — Prev Med ([PMID 42303108](https://pubmed.ncbi.nlm.nih.gov/42303108/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview, red-flags-and-safety-concerns, screening-and-early-detection |
| 2026-04-01 | When the system fails: Barriers to type 1 diabetes medication access and the emergent role of social media support — Diabet Med ([PMID 41996632](https://pubmed.ncbi.nlm.nih.gov/41996632/){target="_blank" rel="noopener"}) | insulin-therapy-and-technology, patient-experience-and-advocacy |
| 2026-04-01 | Persistent Burden of Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Among People With Type 1 Diabetes Despite Technology Use: A Follow-up Survey — Diabetes Care ([PMID 41747141](https://pubmed.ncbi.nlm.nih.gov/41747141/){target="_blank" rel="noopener"}) | hypoglycemia |
| 2026-03-05 | Finerenone in Type 1 Diabetes and Chronic Kidney Disease — N Engl J Med ([PMID 41780000](https://pubmed.ncbi.nlm.nih.gov/41780000/){target="_blank" rel="noopener"}) | clinical-trials-landscape, complications |
| 2026-02-03 | Analysis of glycaemic control and treatment satisfaction with a connected smart pen cap in adults with type 1 diabetes: a randomised, open-label, parallel-group trial — Diabetologia ([PMID 41634174](https://pubmed.ncbi.nlm.nih.gov/41634174/){target="_blank" rel="noopener"}) | insulin-therapy-and-technology |
| 2026-01-20 | Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes — Diabetes ([PMID 41237315](https://pubmed.ncbi.nlm.nih.gov/41237315/){target="_blank" rel="noopener"}) | biomarkers, clinical-trials-landscape, disease-modifying-immunotherapy |
| 2026-01-01 | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358900](https://pubmed.ncbi.nlm.nih.gov/41358900/){target="_blank" rel="noopener"}) | overview |
| 2026-01-01 | Summary of Revisions: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358896](https://pubmed.ncbi.nlm.nih.gov/41358896/){target="_blank" rel="noopener"}) | overview |
| 2026-01-01 | 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358893](https://pubmed.ncbi.nlm.nih.gov/41358893/){target="_blank" rel="noopener"}) | guidelines, overview |
| 2026-01-01 | 7. Diabetes Technology: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358889](https://pubmed.ncbi.nlm.nih.gov/41358889/){target="_blank" rel="noopener"}) | guidelines, overview |
| 2025-12-23 | Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial — JAMA ([PMID 41134589](https://pubmed.ncbi.nlm.nih.gov/41134589/){target="_blank" rel="noopener"}) | complications, insulin-therapy-and-technology, red-flags-and-safety-concerns |
| 2025-12-04 | Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study — EClinicalMedicine ([PMID 41438972](https://pubmed.ncbi.nlm.nih.gov/41438972/){target="_blank" rel="noopener"}) | disease-modifying-immunotherapy, immunopathogenesis |
| 2025-11-08 | Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative — Diabetologia ([PMID 41204978](https://pubmed.ncbi.nlm.nih.gov/41204978/){target="_blank" rel="noopener"}) | staging-and-natural-history |
| 2025-11-02 | Economic evaluation of potential national childhood screening strategies for type 1 diabetes in Australia — Lancet Reg Health West Pac ([PMID 41362419](https://pubmed.ncbi.nlm.nih.gov/41362419/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-11-02 | Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical dissociation between beta-cell preservation and glycemic control — BMC Endocr Disord ([PMID 41267047](https://pubmed.ncbi.nlm.nih.gov/41267047/){target="_blank" rel="noopener"}) | disease-modifying-immunotherapy |
| 2025-11-01 | Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis — JAMA Pediatr ([PMID 40920375](https://pubmed.ncbi.nlm.nih.gov/40920375/){target="_blank" rel="noopener"}) | insulin-therapy-and-technology |
Trials — what has moved¶
19 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 3 |
| trial records updated in the last 2 months | 8 |
| trial records updated in the last 3 months | 8 |
| trial records updated in the last 6 months | 8 |
| trial records updated in the last year | 10 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-10-27 | A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in Peopl | PHASE3 | COMPLETED | 242 | clinical-trials-landscape, complications |
| 2026-10-22 | Verapamil In Preclinical Type 1 Diabetes | PHASE2, PHASE3 | NOT_YET_RECRUITING | 50 | clinical-trials-landscape |
| 2026-10-09 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 7 | beta-cell-replacement, clinical-trials-landscape |
| 2026-09-29 | Teplizumab in Pediatric Stage 2 Type 1 Diabetes | PHASE4 | COMPLETED | 23 | clinical-trials-landscape |
| 2026-09-22 | Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 70 | clinical-trials-landscape |
| 2026-09-09 | Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG | PHASE2 | RECRUITING | 60 | clinical-trials-landscape, disease-modifying-immunotherapy |
| 2026-09-01 | A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type | PHASE3 | RECRUITING | 57 | beta-cell-replacement, clinical-trials-landscape |
| 2026-09-01 | Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes | PHASE2 | ACTIVE_NOT_RECRUITING | 74 | clinical-trials-landscape, disease-modifying-immunotherapy |
| 2026-03-23 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes | PHASE3 | RECRUITING | 10 | clinical-trials-landscape |
| 2025-11-26 | Precision Administration of Anti-thymocyte Globulin With or Without Verapamil | PHASE2 | RECRUITING | 60 | clinical-trials-landscape, disease-modifying-immunotherapy |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | A Study to Learn How Well the Study Treatment Finerenone Works and How | PHASE3 | 242 | Change in UACR From Baseline (Ratio to Baseline) Over 6 Months | 28 | 13 | 2 |
| 2024-06-06 | CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and D | PHASE2 | 212 | Time From Randomization to Confirmed Abnormal Glucose Tolerance Test | 5 | 140 | 0 |
| 2024-04-24 | Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of T | PHASE3 | 328 | Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Me | 18 | 300 | 0 |
| 2020-08-05 | Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" | PHASE2 | 76 | Rate of New Diabetes Per Year | 9 | 66 | 0 |
| 2020-03-02 | ATG-GCSF in New Onset Type 1 Diabetes | PHASE2 | 89 | Change in Area Under the Stimulated C-peptide Curve From Baseline to 1 | 65 | 88 | 0 |
| 2016-08-18 | Rituximab in New Onset Type 1 Diabetes | PHASE2 | 87 | Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a | 20 | 85 | 0 |
| 2016-08-16 | Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitu | PHASE2 | 112 | Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a | 18 | 86 | 0 |
9 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| genetics-and-environmental-triggers | 2026-10-02 | 1 | 27 |
| screening-and-early-detection | 2026-10-02 | 6 | 28 |
| disease-modifying-immunotherapy | 2026-10-01 | 6 | 29 |
| staging-and-natural-history | 2026-10-01 | 3 | 26 |
| beta-cell-replacement | 2026-09-03 | 2 | 25 |
| guidelines | 2026-09-03 | 8 | 32 |
| insulin-therapy-and-technology | 2026-09-02 | 6 | 27 |
| complications | 2026-09-01 | 6 | 28 |
| psychosocial-and-behavioral | 2026-09-01 | 3 | 27 |
| epidemiology-and-burden | 2026-07-02 | 2 | 25 |
| overview | 2026-07-02 | 7 | 41 |
| patient-experience-and-advocacy | 2026-07-02 | 3 | 25 |
| hypoglycemia | 2026-07-01 | 2 | 25 |
| red-flags-and-safety-concerns | 2026-06-01 | 2 | 25 |
| clinical-trials-landscape | 2026-03-05 | 2 | 27 |
| biomarkers | 2026-01-20 | 1 | 28 |
| immunopathogenesis | 2025-12-04 | 1 | 26 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.